Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 275

• Price / Volume Information    Yesterday's Closing Price: $150.15 Daily Weekly Monthly 20 Day Moving Average: 348,623 shares Shares Outstanding: 28.90 (millions) Market Capitalization: $4,339.14 (millions) Beta: 0.67 52 Week High: $219.34 52 Week Low: $122.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.67% 7.96% 12 Week -11.22% -22.67% Year To Date -4.16% -10.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - investors@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer and President Suma M. Krishnan - President Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Dino A. Rossi - Director Peer Information Krystal Biotech, Inc. (CORR.) Krystal Biotech, Inc. (RSPI) Krystal Biotech, Inc. (CGXP) Krystal Biotech, Inc. (BGEN) Krystal Biotech, Inc. (GTBP) Krystal Biotech, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 28.90 Most Recent Split Date: (:1) Beta: 0.67 Market Capitalization: $4,339.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $1.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $5.21 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: 28.80 Trailing 12 Months: 33.44 PEG Ratio: - Price Ratios Price/Book: 4.41 Price/Cash Flow: 32.38 Price / Sales: 13.01 EPS Growth vs. Year Ago Period: 3,900.00% vs. Previous Quarter: -21.05% Sales Growth vs. Year Ago Period: 94.88% vs. Previous Quarter: -3.24% ROE 06/30/25 - - 03/31/25 - 14.64 12/31/24 - 11.41 ROA 06/30/25 - - 03/31/25 - 13.28 12/31/24 - 10.40 Current Ratio 06/30/25 - - 03/31/25 - 9.65 12/31/24 - 7.28 Quick Ratio 06/30/25 - - 03/31/25 - 9.27 12/31/24 - 7.02 Operating Margin 06/30/25 - - 03/31/25 - 40.14 12/31/24 - 34.09 Net Margin 06/30/25 - - 03/31/25 - 37.17 12/31/24 - 30.69 Pre-Tax Margin 06/30/25 - - 03/31/25 - 41.39 12/31/24 - 32.82 Book Value 06/30/25 - - 03/31/25 - 34.07 12/31/24 - 32.90 Inventory Turnover 06/30/25 - - 03/31/25 - 1.04 12/31/24 - 1.17 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©